Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence. It is used for haemorrhages, burns, surgical operations or when the patient shows symptoms of malnutrition or dehydration, chronic infections and renal or liver illnesses. The annual consumption in Spain is about 10 tons but, at a worldwide level, the demand exceeds 500 tons.
Agricultural engineer, Alicia Fernndez San Milln, has developed a novel technique in Spain - plastidial transformation, in order to produce, in a recombinant form, human albumin from tobacco plants. According to her PhD thesis, plastidial transformation is an economically viable alternative, as it enables increasing the levels of HSA by between 10 and a 100 times, compared to levels obtained by nuclear transformation.
The title of the PhD is: "Production of human serum albumin in tobacco plants by means of plastidial transformation". It should be added that this novel technique, fruit of Ms Fernndez San Milln's PhD, has been patented at a world level and there is already a company interested in marketing it.
An efficacious and cheap alternative
Commercial albumin is currently extracted from blood, but the lack of sufficient reserves to cover all worldwide needs has instigated researchers to look for new formulae to multiply this protein. One of the methods most used has been the obtention of HSA from yeasts and mammal cells. However, their high market-place costs have meant that these methods are not competitive. While the price at the pharmacy of albumin produced using plasma is 4 euros per gram, that obtained from yeasts or mammal cells costs between 300 and 4,000 euros
Contact: Garazi Andonegi